BRIEF-BioCardia Provides Update On Timing Of Regulatory Activities Seeking FDA Approval And Japan Pmda Approval For Cardiamp® Cell Therapy For Heart Failure And Helix™ Transendocardial Delivery Catheter

Reuters

Aug 04

BRIEF-<a href="https://laohu8.com/S/BCDA">BioCardia</a> Provides Update On Timing Of Regulatory Activities Seeking FDA Approval And Japan Pmda Approval For Cardiamp® Cell Therapy For Heart Failure And Helix™ Transendocardial Delivery Catheter

Aug 4 (Reuters) - BioCardia Inc BCDA.O:

BIOCARDIA PROVIDES UPDATE ON TIMING OF REGULATORY ACTIVITIES SEEKING FDA APPROVAL AND JAPAN PMDA APPROVAL FOR CARDIAMP® CELL THERAPY FOR HEART FAILURE AND HELIX™ TRANSENDOCARDIAL DELIVERY CATHETER
BIOCARDIA INC - HELIX FDA APPROVAL APPLICATION PLANNED FOR Q3 2025
BIOCARDIA INC - TO SUBMIT CARDIAMP APPROVAL REQUEST TO FDA Q4 2025
BIOCARDIA INC - CARDIAMP CLINICAL CONSULTATION WITH JAPAN PMDA EXPECTED Q4 2025

Source text: ID:nGNX76cg6m

Further company coverage: BCDA.O

((Reuters.Briefs@thomsonreuters.com;))

Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.

Most Discussed

{"basename":"","ssrTDKData":{"titleTemplate":"%s - Tiger Brokers","title":"Tiger Brokers | Global Stocks, Options & Futures Trading App","description":"Tiger Brokers, one-stop investment in US stocks, SGX stocks, HK stocks, A-shares & other global assets. One of the best stock trading platforms in Singapore.","keywords":"tiger brokers,tiger trade,tiger brokers singapore,broker online,stock trading in singapore,share trading singapore,brokerage firm singapore,trading app,stock broker singapore,stock trading platforms,trading account","social":{"ogDescription":"Tiger Brokers, one-stop investment in US stocks, SGX stocks, HK stocks, A-shares & other global assets. One of the best stock trading platforms in Singapore.","ogImage":"https://c1.itigergrowtha.com/portal5/static/media/og-logo.be62fbe1.png","ogUrl":"https://www.itiger.com/news/2556662800"},"companyName":"Tiger Brokers"},"pageData":{"isMobile":false,"isTiger":false,"isTTM":true,"region":"SGP","license":"TBSG","edition":"fundamental"},"isCrawlerRequest":true,"__swrFallback__":{"@#url:\"https://stock-news.skytigris.cn/v3/news\",params:#id:\"2556662800\",edition:\"fundamental\",auth_exemption:1,,,undefined,":{"share":"https://ttm.financial/m/news/2556662800?lang=en_US&edition=fundamental","thumbnail":"","is_english":true,"pubTime":"2025-08-04 18:04","share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","id":"2556662800","market":"us","top_or_hot":-1,"title":"BRIEF-BioCardia Provides Update On Timing Of Regulatory Activities Seeking FDA Approval And Japan Pmda Approval For Cardiamp® Cell Therapy For Heart Failure And Helix™ Transendocardial Delivery Catheter","media":"Reuters","content":"<html xmlns=\"http://www.w3.org/1999/xhtml\"><head><title>BRIEF-<a href=\"https://laohu8.com/S/BCDA\">BioCardia</a> Provides Update On Timing Of Regulatory Activities Seeking FDA Approval And Japan Pmda Approval For Cardiamp® Cell Therapy For Heart Failure And Helix™ Transendocardial Delivery Catheter</title></head><body><p><span>Aug 4 (Reuters)</span><span> - </span>BioCardia Inc <span>BCDA.O</span>:</p><ul><li><p>BIOCARDIA PROVIDES UPDATE ON TIMING OF REGULATORY ACTIVITIES SEEKING FDA APPROVAL AND JAPAN PMDA APPROVAL FOR CARDIAMP® CELL THERAPY FOR HEART FAILURE AND HELIX™ TRANSENDOCARDIAL DELIVERY CATHETER</p></li><li><p><a href=\"https://laohu8.com/S/BCDAW\">BIOCARDIA INC</a> - HELIX FDA APPROVAL APPLICATION PLANNED FOR Q3 2025</p></li><li><p>BIOCARDIA INC - TO SUBMIT CARDIAMP APPROVAL REQUEST TO FDA Q4 2025</p></li><li><p>BIOCARDIA INC - CARDIAMP CLINICAL CONSULTATION WITH JAPAN PMDA EXPECTED Q4 2025</p></li></ul><p>Source text: <span>ID:nGNX76cg6m</span></p><p>Further company coverage: <span>BCDA.O</span></p><p> ((Reuters.Briefs@thomsonreuters.com;))</p></body></html>","source":null,"html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>BRIEF-BioCardia Provides Update On Timing Of Regulatory Activities Seeking FDA Approval And Japan Pmda Approval For Cardiamp® Cell Therapy For Heart Failure And Helix™ Transendocardial Delivery Catheter</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nBRIEF-BioCardia Provides Update On Timing Of Regulatory Activities Seeking FDA Approval And Japan Pmda Approval For Cardiamp® Cell Therapy For Heart Failure And Helix™ Transendocardial Delivery Catheter\n</h2>\n\n<h4 class=\"meta\">\n\n\n<a class=\"head\" href=\"https://laohu8.com/wemedia/1032215980\">\n\n\n<div class=\"h-thumb\" style=\"background-image:url(https://community-static.tradeup.com/news/4567337cbdf294b657b1fa87c5488b48);background-size:cover;\"></div>\n\n<div class=\"h-content\">\n<p class=\"h-name\">Reuters </p>\n<p class=\"h-time\">2025-08-04 18:04</p>\n</div>\n\n</a>\n\n\n</h4>\n\n</header>\n<article>\n<html xmlns=\"http://www.w3.org/1999/xhtml\"><head><title>BRIEF-<a href=\"https://laohu8.com/S/BCDA\">BioCardia</a> Provides Update On Timing Of Regulatory Activities Seeking FDA Approval And Japan Pmda Approval For Cardiamp® Cell Therapy For Heart Failure And Helix™ Transendocardial Delivery Catheter</title></head><body><p><span>Aug 4 (Reuters)</span><span> - </span>BioCardia Inc <span>BCDA.O</span>:</p><ul><li><p>BIOCARDIA PROVIDES UPDATE ON TIMING OF REGULATORY ACTIVITIES SEEKING FDA APPROVAL AND JAPAN PMDA APPROVAL FOR CARDIAMP® CELL THERAPY FOR HEART FAILURE AND HELIX™ TRANSENDOCARDIAL DELIVERY CATHETER</p></li><li><p><a href=\"https://laohu8.com/S/BCDAW\">BIOCARDIA INC</a> - HELIX FDA APPROVAL APPLICATION PLANNED FOR Q3 2025</p></li><li><p>BIOCARDIA INC - TO SUBMIT CARDIAMP APPROVAL REQUEST TO FDA Q4 2025</p></li><li><p>BIOCARDIA INC - CARDIAMP CLINICAL CONSULTATION WITH JAPAN PMDA EXPECTED Q4 2025</p></li></ul><p>Source text: <span>ID:nGNX76cg6m</span></p><p>Further company coverage: <span>BCDA.O</span></p><p> ((Reuters.Briefs@thomsonreuters.com;))</p></body></html>\n\n</article>\n</div>\n</body>\n</html>\n","isBrief":false,"type":0,"news_type":1,"symbol":"BK4139","symbol_name":"生物科技","start_time":0,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20250804:nTUA49VCHL:1","article_id":"2556662800","we_media_id":"1032215980","thumbnails":[],"rights":null,"url":"https://stock-news.laohu8.com/highlight/detail?id=2556662800","pubTimestamp":1754301889,"columns":[],"sourceInfo":null,"weMediaInfo":{"media_name":"Reuters","introduction":"Reuters.com brings you the latest news from around the world, covering breaking news in markets, business, politics, entertainment and technology","home_visible":1,"id":"1032215980","head_image":"https://community-static.tradeup.com/news/4567337cbdf294b657b1fa87c5488b48"},"summary":"BRIEF-BioCardia Provides Update On Timing Of Regulatory Activities Seeking FDA Approval And Japan Pmda Approval For Cardiamp Cell Therapy For Heart Failure And Helix Transendocardial Delivery Catheter","collect":0,"end_time":0,"defaultTopTitle":"","property":[],"viewcount":null,"language":"en","relate_stocks":{"BK4139":"生物科技","BCDA":"BioCardia"},"translate_title":"简介-BioCardia提供了Cardiamp寻求FDA批准和日本Pmda批准的监管活动时间的最新信息®心力衰竭和Helix的细胞治疗™经心内膜输送导管","themeId":null,"isJumpTheme":false,"ttsUrl":null,"symbols_score_info":{"BCDA":0.9},"content_text":"BRIEF-BioCardia Provides Update On Timing Of Regulatory Activities Seeking FDA Approval And Japan Pmda Approval For Cardiamp® Cell Therapy For Heart Failure And Helix™ Transendocardial Delivery CatheterAug 4 (Reuters) - BioCardia Inc BCDA.O:BIOCARDIA PROVIDES UPDATE ON TIMING OF REGULATORY ACTIVITIES SEEKING FDA APPROVAL AND JAPAN PMDA APPROVAL FOR CARDIAMP® CELL THERAPY FOR HEART FAILURE AND HELIX™ TRANSENDOCARDIAL DELIVERY CATHETERBIOCARDIA INC - HELIX FDA APPROVAL APPLICATION PLANNED FOR Q3 2025BIOCARDIA INC - TO SUBMIT CARDIAMP APPROVAL REQUEST TO FDA Q4 2025BIOCARDIA INC - CARDIAMP CLINICAL CONSULTATION WITH JAPAN PMDA EXPECTED Q4 2025Source text: ID:nGNX76cg6mFurther company coverage: BCDA.O ((Reuters.Briefs@thomsonreuters.com;))","kind":"highlight","is_publish_news":true,"is_publish_highlight":false,"is_publish_live":false,"is_publish_wemedia":null,"editions":null,"column":"","sentiment":"1","news_tag":"policyRegulatory","news_rank":0,"symbols":[],"gpt_button":1,"need_auth":false,"code":"91000000","status":"200"}}}